Dec 4 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:
AMYLYX PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 LUCIDITY TRIAL DESIGN FOR GLP-1 RECEPTOR ANTAGONIST (AVEXITIDE) IN POST-BARIATRIC HYPOGLYCEMIA
AMYLYX PHARMACEUTICALS INC - PHASE 3 LUCIDITY TRIAL TO EVALUATE REDUCTION IN HYPOGLYCEMIA EVENTS
AMYLYX PHARMACEUTICALS INC - FIRST PARTICIPANT IN LUCIDITY TRIAL EXPECTED IN Q1 2025
AMYLYX PHARMACEUTICALS INC - EXPECTS FIRST STUDY PARTICIPANT DOSED IN LUCIDITY IN Q1 2025 AND TOPLINE RESULTS IN 2026
Source text: ID:nBw7dlJTJa
Further company coverage: AMLX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.